In a recent ISB Research Roundtable, ISB President Dr. Jim Heath shared new findings connecting Long COVID to immune dysfunction and autoimmune diseases, and explained how artificial intelligence could accelerate the search for answers — and potentially new treatments — for millions of people living with the condition.
By integrating single-cell, proteomic, genetic, clinical, and laboratory data, the team found that these cells adopt molecular features also seen in established autoimmune diseases. The findings help explain how viral infections can disrupt immune regulation and may provide a framework for understanding and eventually preventing autoimmune complications following infection.
ISB President Dr. Jim Heath talks with Nobel laureate and Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center Dr. Jim Allison and Apricity Health CEO Dr. Lynda Chin. Drs. Heath, Allison and Chin discuss disparities in cancer care and ways to bring state-of-the-art care from big cities and major academic centers to rural and underserved areas.
The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.